摘要
曲妥珠单抗是靶向人表皮生长因子2(c-erbB-2,HER2)的单克隆抗体,治疗HER2阳性乳腺癌疗效确切,然而其客观反应率并不高,而且多数患者在1年内出现获得性耐药。目前的基础研究初步解释了曲妥珠单抗耐药的分子机制,一些新的治疗策略为曲妥珠单抗耐药患者带来新的希望。本文综述了近年来有关曲妥珠单抗的耐药机制及其应对策略的研究进展。
Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 ( HER2 ). Trastuzumab has shown clinical activity in HER2-positive breast cancers. However, the patient objective response rates to trastuzumab monotherapy were low and the majority of patients with metastatic breast cancer demonstrated disease progression within 1 year after treatment initiation. Preclinical studies have indicated several molecular mechanisms that could contribute to the development of trastuzumab resistance. Novel therapies offer hope for patients with trastuzumab resistance.
出处
《军事医学科学院院刊》
CSCD
北大核心
2008年第4期392-394,共3页
Bulletin of the Academy of Military Medical Sciences